Cargando…

Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease

Coronavirus disease 19 (COVID-19) is the latest pandemic resulted from the coronavirus family. Due to the high prevalence of this disease, its high mortality rate, and the lack of effective treatment, the need for affordable and accessible drugs is one of the main challenges in this regard. It has b...

Descripción completa

Detalles Bibliográficos
Autores principales: Balmeh, Negar, Mahmoudi, Samira, Fard, Najaf Allahyari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832255/
https://www.ncbi.nlm.nih.gov/pubmed/33521241
http://dx.doi.org/10.1016/j.imu.2021.100515
_version_ 1783641796630282240
author Balmeh, Negar
Mahmoudi, Samira
Fard, Najaf Allahyari
author_facet Balmeh, Negar
Mahmoudi, Samira
Fard, Najaf Allahyari
author_sort Balmeh, Negar
collection PubMed
description Coronavirus disease 19 (COVID-19) is the latest pandemic resulted from the coronavirus family. Due to the high prevalence of this disease, its high mortality rate, and the lack of effective treatment, the need for affordable and accessible drugs is one of the main challenges in this regard. It has been proved that RdRp, 3CL, Spike, and Nucleocapsid are the most important viral proteins playing vital roles in the processes of proliferation and infection. Therefore, we started studying a wide range of bio-peptides and then conducted molecular docking analyses to investigate their binding affinity for the inhibition of these proteins. After obtaining the best bio-peptides with the highest affinity scores, they were examined for further study and then manipulated to eliminate their side effects. Additionally, the molecular dynamic simulation was performed to validate the structure and interaction stability. The results of this study reveal that glycocin F from Lactococcus lactis and lactococcine G from Lactobacillus plantarum had the high affinities to bind to the viral proteins, and the manipulation of their sequence also led to the side effects’ elimination. In addition, in some cases, their affinities to attach the SARS-CoV-2 proteins have increased. It seems that these two drugs which were discovered and designed, are optimal for treating the COVID-19 infection. However, experimental and pre-clinical studies are necessary to assay their therapeutic effects.
format Online
Article
Text
id pubmed-7832255
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78322552021-01-26 Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease Balmeh, Negar Mahmoudi, Samira Fard, Najaf Allahyari Inform Med Unlocked Article Coronavirus disease 19 (COVID-19) is the latest pandemic resulted from the coronavirus family. Due to the high prevalence of this disease, its high mortality rate, and the lack of effective treatment, the need for affordable and accessible drugs is one of the main challenges in this regard. It has been proved that RdRp, 3CL, Spike, and Nucleocapsid are the most important viral proteins playing vital roles in the processes of proliferation and infection. Therefore, we started studying a wide range of bio-peptides and then conducted molecular docking analyses to investigate their binding affinity for the inhibition of these proteins. After obtaining the best bio-peptides with the highest affinity scores, they were examined for further study and then manipulated to eliminate their side effects. Additionally, the molecular dynamic simulation was performed to validate the structure and interaction stability. The results of this study reveal that glycocin F from Lactococcus lactis and lactococcine G from Lactobacillus plantarum had the high affinities to bind to the viral proteins, and the manipulation of their sequence also led to the side effects’ elimination. In addition, in some cases, their affinities to attach the SARS-CoV-2 proteins have increased. It seems that these two drugs which were discovered and designed, are optimal for treating the COVID-19 infection. However, experimental and pre-clinical studies are necessary to assay their therapeutic effects. The Authors. Published by Elsevier Ltd. 2021 2021-01-12 /pmc/articles/PMC7832255/ /pubmed/33521241 http://dx.doi.org/10.1016/j.imu.2021.100515 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Balmeh, Negar
Mahmoudi, Samira
Fard, Najaf Allahyari
Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease
title Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease
title_full Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease
title_fullStr Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease
title_full_unstemmed Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease
title_short Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease
title_sort manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for covid-19 disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832255/
https://www.ncbi.nlm.nih.gov/pubmed/33521241
http://dx.doi.org/10.1016/j.imu.2021.100515
work_keys_str_mv AT balmehnegar manipulatedbioantimicrobialpeptidesfromprobioticbacteriaasproposeddrugsforcovid19disease
AT mahmoudisamira manipulatedbioantimicrobialpeptidesfromprobioticbacteriaasproposeddrugsforcovid19disease
AT fardnajafallahyari manipulatedbioantimicrobialpeptidesfromprobioticbacteriaasproposeddrugsforcovid19disease